Clinical trials: Relapse Management
Multiple Sclerosis
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
Ofatumumab is a novel Immunoglobulin 1ĸ ( IgG1ĸ) lytic monoclonal antibody (mAb) that specifically binds to the human Cluster of Differentiation 20 (CD20) antigen of which expression is restricted to B lymphocytes from the pre-B…
- Trial name
- MIRROR (NCT01457924)
- Testing
- Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg
- Where
- 61 sites in United States, Bulgaria and 9 more
- Volunteers
- 232 people
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Superficial Bladder Cancer
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed…
- Trial name
- NCT01687244
- Testing
- INSTILADRIN
- Volunteers
- 40 people
- Sponsor
- FKD Therapies Oy
Myeloid Malignancies, Acute Myeloid Leukemia
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic…
- Conditions
- Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- NCT05115630
- Testing
- Cyclophosphamide, Mesna, Filgrastim
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara…
- Trial name
- NCT03277105
- Testing
- Dara SC, Dara IV
- Where
- 146 sites in United States, Australia and 16 more
- Volunteers
- 522 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to evaluate the efficacy of natalizumab 300 milligrams (mg) subcutaneous (SC) every 4 weeks (Q4W) administrations up to 24 weeks in Japanese participants with relapsing-remitting multiple…
- Trial name
- NCT05265728
- Testing
- Natalizumab
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Biogen
Relapsed Acute Leukemia, Refractory Acute Leukemia
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
1.1 Primary Objectives To determine the feasibility, tolerability, and toxicities of administering the selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and Mitoxantrone for adults with relapsed and…
- Conditions
- Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
- Trial name
- NCT01701375
- Testing
- PD 0332991
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aplastic Anemia
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric…
- Trial name
- NCT03025698
- Testing
- Eltrombopag, hATG, CsA
- Where
- 20 sites in United States, Hong Kong and 4 more
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Acute Lymphoblastic Leukemia
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2…
- Trial name
- NCT04524455
- Testing
- Blinatumomab, AMG 404, Dexamethasone Premedication
- Where
- 19 sites in United States, Australia and 7 more
- Volunteers
- 17 people
- Sponsor
- Amgen
Plasma Cell Myeloma Recurrent
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study…
- Trial name
- IRAKLIA (NCT05405166)
- Testing
- Isatuximab IV, Isatuximab SC, Dexamethasone
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 531 people
- Sponsor
- Sanofi
Tobacco Use Disorder
Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Recent research on the effects of nicotine on the brain and behavior presents an opportunity to advance medication development. The purpose of this study is to develop a laboratory model for early-stage testing of new and…
- Trial name
- NCT00136838
- Testing
- Neutral or active cigarette cues
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Hodgkin Disease, Lymphoma
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases
- Trial name
- NCT02663297
- Testing
- ATLCAR.CD30 cells
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Part 1: The primary objective is to evaluate the efficacy of natalizumab extended interval dosing (EID) (every 6 weeks [Q6W]) in participants who have previously been treated with natalizumab standard interval dosing (SID) (every…
- Trial name
- NCT03689972
- Testing
- Natalizumab
- Where
- 107 sites in United States, Australia and 9 more
- Volunteers
- 585 people
- Sponsor
- Biogen
Cocaine Dependence
Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse
This is a residential pilot trial to evaluate the pharmacodynamic interaction between zonisamide and cocaine, with the goal of evaluating zonisamide's potential for the treatment of cocaine dependence.
- Trial name
- NCT01137890
- Testing
- Zonisamide, Cocaine Hydrochloride, Neurocognitive and Performance Battery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Follicular Lymphoma
Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
This French national, multicenter, prospective, longitudinal, observational study will describe the treatment modalities of a cohort of patients with relapsed or refractory follicular non-Hodgkin's lymphoma, with evaluation of…
- Trial name
- NCT02316613
- Testing
- Rituximab
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Disease, Non Hodgkin Lymphoma
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
This protocol is broken up into 2 portions to determine the maximum tolerated dose for treating patients with a type of lymph gland disease.
- Conditions
- Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
- Trial name
- ALCI (NCT00062868)
- Testing
- LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C)
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- Baylor College of Medicine
Cocaine Dependence
Modafinil for Smoked Cocaine Self-Administration
Modafinil has been reported to reduce cocaine use in a clinical sample of infrequent users (2 days/week), but the effects of modafinil on cocaine self-administration in the laboratory have not been studied.
- Trial name
- NCT01778010
- Testing
- Modafinil 0 mg, Modafinil 200 mg, Modafinil 400 mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Relapsing Remitting Multiple Sclerosis
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
Single site, open label, randomized design in patients with relapsing forms of Multiple Sclerosis. At the Screening Visit, the patient will be given a diary containing the MAGIS scale to be completed once a day for the first two…
- Trial name
- IIT9 (NCT02217982)
- Testing
- Simethicone, Loperamide, Peanut Butter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rocky Mountain MS Research Group, LLC